Journal article icon

Journal article

Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups

Abstract:
OBJECTIVES: The severity of skin involvement in diffuse cutaneous systemic sclerosis (dcSSc) depends on stage of disease and differs between anti-RNA-polymerase III (ARA) and anti-topoisomerase antibody (ATA) subsets. We have investigated cellular differences in well-characterised dcSSc patients compared with healthy controls (HCs). METHODS: We performed single-cell RNA sequencing on 4 mm skin biopsy samples from 12 patients with dcSSc and HCs (n=3) using droplet-based sequencing (10× genomics). Patients were well characterised by stage (>5 or <5 years disease duration) and autoantibody (ATA+ or ARA+). Analysis of whole skin cell subsets and fibroblast subpopulations across stage and ANA subgroup were used to interpret potential cellular differences anchored by these subgroups. RESULTS: Fifteen forearm skin biopsies were analysed. There was a clear separation of SSc samples, by disease, stage and antibody, for all cells and fibroblast subclusters. Further analysis revealed differing cell cluster gene expression profiles between ATA+ and ARA+ patients. Cell-to-cell interaction suggest differing interactions between early and late stages of disease and autoantibody. TGFβ response was mainly seen in fibroblasts and smooth muscle cells in early ATA+dcSSc skin samples, whereas in early ARA+dcSSc patient skin samples, the responding cells were endothelial, reflect broader differences between clinical phenotypes and distinct skin score trajectories across autoantibody subgroups of dcSSc. CONCLUSIONS: We have identified cellular differences between the two main autoantibody subsets in dcSSc (ARA+ and ATA+). These differences reinforce the importance of considering autoantibody and stage of disease in management and trial design in SSc
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1136/ard-2023-224184
Publication website:
https://discovery.ucl.ac.uk/10175448/1/ard-2023-224184.full.pdf

Authors

More by this author
Role:
Author
ORCID:
0000-0002-5926-3900
More by this author
Role:
Author
ORCID:
0000-0002-3624-2410
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Role:
Author
ORCID:
0000-0001-5474-0053
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0001-6924-6402


More from this funder
Funder identifier:
10.13039/501100000265
Grant:
MR/T001631/1
More from this funder
Funder identifier:
10.13039/100004330


Publisher:
Elsevier
Journal:
Annals of the Rheumatic Diseases More from this journal
Volume:
82
Issue:
12
Pages:
1568-1579
Publication date:
2023-08-14
DOI:
EISSN:
1468-2060
ISSN:
0003-4967


Language:
English
Keywords:
Pubs id:
1511225
Local pid:
pubs:1511225
Source identifiers:
W4385802294
Deposit date:
2026-05-12
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP